Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 154 Brain Neoplasms 73 Glioma 69 Central Nervous System Neoplasms 50 Gliosarcoma 46 Astrocytoma 37 Melanoma 36 Oligodendroglioma 29 Neuroblastoma 17 Neoplasm Metastasis 14 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 11 Sarcoma, Ewing 10 Sarcoma 10 Neoplasms 10 Medulloblastoma 10 Recurrence 9 Neuroendocrine Tumors 9 Lymphoma 8 Ependymoma 8 Breast Neoplasms 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Diffuse Intrinsic Pontine Glioma 7 Colorectal Neoplasms 7 Carcinoma, Neuroendocrine 6 Adenoma, Islet Cell 6 Uveal Melanoma 5 Spinal Cord Neoplasms 5 Pheochromocytoma 5

Interventions

Gemcitabine 45 Cisplatin 34 Oxaliplatin 23 Capecitabine 17 Fluorouracil 13 Leucovorin 12 pembrolizumab 11 lenvatinib 11 durvalumab 10 S 1 (combination) 10 Irinotecan 10 Bevacizumab 9 apatinib 7 Nivolumab 7 tremelimumab 6 Trastuzumab 5 envafolimab 4 atezolizumab 4 Injections 4 Docetaxel 4 trametinib 3 titanium silicide 3 tislelizumab 3 irinotecan sucrosofate 3 camrelizumab 3 Radiotherapy 3 Drug Therapy 3 zanidatamab 2 toripalimab 2 surufatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biliary Tract Neoplasms × Temozolomide × Clear all

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡